AlphAIAlphAI — Financial news for AI agents
investing.comOCT 283 min read$LH

Labcorp Q3 2026 slides: margins expand for sixth straight quarter

Labcorp reported Q3 2026 earnings with revenue of $3.81B, beating estimates, and raised its full-year outlook. Adjusted EPS was $4.78, up 14.4% YoY. Margins expanded for the sixth straight quarter, driven by strong diagnostics and biopharma segments. Shares surged 9.54% post-results.

Original reporting
investing.com
Published Oct 28, 2026, 2:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LH
Bullish
high confidence
Mentioned
$LH
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LHBullishHigh
01

Why it matters

The earnings beat and guidance raise expectations for the healthcare sector, supporting a bullish bias on LH.

02

Market read

Labcorp's earnings and guidance lift are likely to drive short-term upside and influence related healthcare stocks.

03

What to watch

Potential headwinds from foreign currency exposure and upcoming competition in specialty testing.

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

Labcorp disclosed its Q3 2026 supplemental results, highlighting margin expansion and a stronger outlook.

Company-level read

Ticker impact

$LHBullishHigh confidence
Context

Labcorp reported Q3 2026 earnings beating estimates and raised full-year guidance, causing a 9.5% share surge.

Expected impact

upward pressure as investors price in higher revenue and EPS outlook

Evidence & confidence

Margin expansion, revenue beat, and guidance lift are material and new, likely to sustain price gains.

Market effects

Sector

Diagnostics and biopharma lab services sector may see broader optimism.

Regional

U.S. healthcare stocks could rally on the earnings beat.

Global

Limited to U.S. markets; no immediate global ripple.

Counterpoint

What could challenge this read

If guidance upgrades are already priced in, the stock could face short-term profit taking.

Key entities

  • Company
    Labcorp

    Laboratory Corporation of America Holdings, provider of diagnostic and biopharma services.

Read at source← All news

StoryLabcorp posts Q3 2026 revenue and adjusted EPS growth and lifts full‑year guidance

Also covered by

5 outlets

Related articles

OCT 28
$LHHighAI 9/10

Labcorp adds more diagnostic services

Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.

thetimesnews.com2 min
OCT 28
$LHMedAI 8/10

Labcorp Boosts FY26 Outlook - Update

Labcorp (LH) raised its FY26 adjusted earnings guidance to $18.30-$18.70 per share and revenue to $14.779-$14.887 billion, up from prior estimates. The company also declared a $0.72 quarterly dividend. LH stock is up 1.39% in pre-market trading.

rttnews.com1 min
OCT 28
$LHMedAI 9/10

Labcorp’s (NYSE:LH) Q3 2026 sales beat estimates

Labcorp reported Q3 2026 revenue of $3.81B, exceeding estimates by 1.2% and growing 6.9% YoY. Adjusted EPS was $4.78, a 2.9% beat. The company raised full-year revenue and EPS guidance. Operating margin remained steady at 10.6%, while free cash flow margin improved to 10.8%. Organic revenue grew 5.5% YoY.

finance.yahoo.com2 min
OCT 28
$LHHighAI 8/10

Labcorp shares edge up on beating estimates, raising guidance

Labcorp Holdings Inc. (NYSE:LH) reported Q3 earnings of $4.78 per share, beating estimates by $0.13, with revenue of $3.81 billion, up 6.9% YoY. The company raised full-year guidance for revenue growth to 5.9%-6.7% and adjusted EPS to $18.30-$18.70. Shares rose 1.46% in pre-market trading. Labcorp also announced four acquisitions and paid $58.2 million in dividends.

investing.com2 min